Free Trial

Natera (NTRA) Stock Price, News & Analysis

Natera logo
$167.26 -2.10 (-1.24%)
(As of 11/22/2024 ET)

About Natera Stock (NASDAQ:NTRA)

Key Stats

Today's Range
$163.07
$170.59
50-Day Range
$117.67
$169.20
52-Week Range
$53.62
$171.95
Volume
1.48 million shs
Average Volume
1.35 million shs
Market Capitalization
$22.08 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$140.59
Consensus Rating
Buy

Company Overview

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Natera Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
56th Percentile Overall Score

NTRA MarketRank™: 

Natera scored higher than 56% of companies evaluated by MarketBeat, and ranked 492nd out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Natera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Natera has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Natera's stock forecast and price target.
  • Earnings Growth

    Earnings for Natera are expected to grow in the coming year, from ($1.66) to ($1.29) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Natera is -95.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Natera is -95.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Natera has a P/B Ratio of 25.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Natera's valuation and earnings.
  • Percentage of Shares Shorted

    2.82% of the outstanding shares of Natera have been sold short.
  • Short Interest Ratio / Days to Cover

    Natera has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Natera has recently decreased by 1.59%, indicating that investor sentiment is improving.
  • Dividend Yield

    Natera does not currently pay a dividend.

  • Dividend Growth

    Natera does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.82% of the outstanding shares of Natera have been sold short.
  • Short Interest Ratio / Days to Cover

    Natera has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Natera has recently decreased by 1.59%, indicating that investor sentiment is improving.
  • News Sentiment

    Natera has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 25 news articles for Natera this week, compared to 9 articles on an average week.
  • Search Interest

    23 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 475% compared to the previous 30 days.
  • MarketBeat Follows

    15 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,325,804.00 in company stock.

  • Percentage Held by Insiders

    Only 7.60% of the stock of Natera is held by insiders.

  • Percentage Held by Institutions

    99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Natera's insider trading history.
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Stock News Headlines

Natera, Inc. (NASDAQ:NTRA) Director Sells $1,548,926.36 in Stock
2025: Digital Asset Insights You Need to Know
Cryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.
Healthcare stocks
3 Under-the-Radar Healthcare Companies (NTRA)
While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.
Natera, Inc. (NASDAQ:NTRA) CFO Sells $235,955.70 in Stock
Natera (NASDAQ:NTRA) Stock Price Down 3.1% Following Insider Selling
See More Headlines

NTRA Stock Analysis - Frequently Asked Questions

Natera's stock was trading at $62.64 on January 1st, 2024. Since then, NTRA shares have increased by 167.0% and is now trading at $167.26.
View the best growth stocks for 2024 here
.

Natera, Inc. (NASDAQ:NTRA) released its quarterly earnings data on Tuesday, November, 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera's revenue for the quarter was up 63.9% on a year-over-year basis.

Natera (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Top institutional shareholders of Natera include Fred Alger Management LLC (3.24%), State Street Corp (2.65%), Wellington Management Group LLP (2.12%) and Massachusetts Financial Services Co. MA (2.01%). Insiders that own company stock include Matthew Rabinowitz, Daniel Rabinowitz, Steven Leonard Chapman, John Fesko, Solomon Moshkevich, Michael Burkes Brophy, Herm Rosenman, Jonathan Sheena, James Healy, Gail Boxer Marcus, Rowan E Chapman, Robert Alan Schueren and Roelof Botha.
View institutional ownership trends
.

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
11/12/2024
Today
11/22/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
3,293
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$140.59
High Stock Price Target
$200.00
Low Stock Price Target
$70.00
Potential Upside/Downside
-15.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
17 Analysts

Profitability

Net Income
$-434,800,000.00
Pretax Margin
-13.87%

Debt

Sales & Book Value

Annual Sales
$1.08 billion
Book Value
$6.65 per share

Miscellaneous

Free Float
121,987,000
Market Cap
$22.08 billion
Optionable
Optionable
Beta
1.53

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:NTRA) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners